Autophagy is a cellular degradation pathway where autophagosomes engulf cytoplasmic components and deliver them to lysosomes for recycling. Basal autophagy maintains protein and organelle quality control, but excessive autophagy can trigger cell death (autophagic cell death). Defective autophagy accumulates protein aggregates and damaged organelles, contributing to Alzheimer's disease, Parkinson's disease, and cardiomyopathy.
Trace the autophagy cascade from initiation through phagophore formation and lysosomal fusion. Understand mTOR as a negative regulator—how nutrient starvation induces autophagy. Study selective autophagy (mitophagy, xenophagy).
Autophagy is not always protective—excessive autophagy can be lethal. The relationship between autophagy and apoptosis is complex; often both are activated simultaneously in response to cellular stress.
From your cell biology foundation, you know that cells are not static factories—they are continuously synthesizing and degrading proteins, replacing worn organelles, and managing quality control of their own internal machinery. Autophagy (from the Greek for "self-eating") is one of the cell's two major protein degradation systems, alongside the ubiquitin-proteasome system. While the proteasome handles small, short-lived proteins one at a time, autophagy is a bulk degradation pathway capable of engulfing entire organelles, large protein aggregates, and intracellular pathogens. Think of the proteasome as recycling individual bottles, and autophagy as the system that handles furniture and appliances.
The macroautophagy pathway—the dominant form—begins with the formation of a cup-shaped membrane structure called a phagophore, which elongates and wraps around cytoplasmic cargo to form a double-membrane vesicle called the autophagosome. The autophagosome then fuses with a lysosome, exposing the contents to hydrolytic enzymes that degrade them into amino acids, fatty acids, and sugars that are exported back to the cytoplasm for reuse. The master regulator of this process is mTOR (mechanistic target of rapamycin): when nutrients are abundant, mTOR is active and phosphorylates autophagy-initiating proteins to suppress the pathway. When nutrients are scarce—during fasting, amino acid deprivation, or hypoxia—mTOR is inhibited, releasing the brake on autophagy. This is why fasting powerfully induces autophagy, and why mTOR inhibitors (like rapamycin) are used experimentally to trigger autophagy in research contexts.
Cells also perform selective autophagy, targeting specific cargoes for degradation rather than bulk cytoplasm. Mitophagy selectively removes damaged mitochondria—quality-control for the cell's energy generators. Damaged mitochondria that fail to maintain their membrane potential are tagged with ubiquitin and recognized by autophagy receptors (like p62/SQSTM1) that recruit the phagophore directly to the target. Xenophagy performs the same function for intracellular bacteria, capturing pathogens in autophagosomes before they can replicate. These selective pathways explain why defects in autophagy have such specific disease consequences: if mitophagy is impaired, dysfunctional mitochondria accumulate and generate excess reactive oxygen species; if xenophagy is compromised, intracellular pathogens like Mycobacterium tuberculosis can exploit this blind spot.
The disease relevance of autophagy turns on a central paradox: the same pathway can be cytoprotective or cytodestructive depending on context. In neurodegenerative diseases, impaired autophagy allows misfolded proteins to accumulate—the amyloid-beta and tau aggregates of Alzheimer's disease, the alpha-synuclein Lewy bodies of Parkinson's disease, and the polyglutamine aggregates of Huntington's disease all represent failures of proteostasis (protein homeostasis) that functional autophagy would prevent. In cancer, the picture reverses: early in tumor development, autophagy suppresses transformation by clearing damaged organelles; but in established tumors under metabolic stress, cancer cells hijack autophagy to survive chemotherapy and nutrient deprivation, making it a potential resistance mechanism. This dual role—guardian in healthy tissue, survival advantage in stressed tumors—is why autophagy modulation is one of the more complex targets in cancer therapeutics.